Stock Price Movement and Market Context
On 25 Nov 2025, Indo US Bio-Tech's share price touched an intraday low of Rs.112.6, representing a fall of 3.43% on the day. This decline extended a two-day losing streak, during which the stock recorded a cumulative return of -10.78%. The stock's performance notably lagged behind its sector, which gained 4.27% on the same day, and underperformed the broader market indices, with the Sensex opening higher at 85,008.93 points and trading close to its 52-week high of 85,801.70.
Indo US Bio-Tech's share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward pressure. In contrast, the Sensex maintains a bullish stance, trading above its 50-day moving average, which itself is positioned above the 200-day moving average. Mid-cap stocks are leading the market rally, with the BSE Mid Cap index gaining 0.13% on the day.
Strong fundamentals, solid momentum, fair price – This Large Cap from the NBFC sector checks every box for our Top 1%. This should definitely be on your radar!
- - Complete fundamentals package
- - Technical momentum confirmed
- - Reasonable valuation entry
One-Year Performance and Comparative Analysis
Over the past year, Indo US Bio-Tech's stock has recorded a return of -56.35%, a stark contrast to the Sensex's positive return of 6.03% during the same period. The stock's 52-week high was Rs.386, indicating a substantial decline from its peak. This underperformance is also evident when compared to the BSE500 index, which generated returns of 4.66% over the last year.
The stock's relative weakness is further highlighted by its underperformance against the broader agricultural sector, which has shown resilience and growth. Indo US Bio-Tech's share price decline has occurred despite the sector's overall gains, underscoring company-specific factors influencing investor sentiment.
Financial Metrics and Profitability Trends
Recent quarterly results reveal that Indo US Bio-Tech's profit after tax (PAT) stood at Rs.3.45 crores, reflecting a decline of 22.4% compared to the previous four-quarter average. The company's profit before depreciation, interest, and taxes (PBDIT) for the quarter was Rs.4.17 crores, marking the lowest level recorded in recent periods. Operating profit to net sales ratio for the quarter was 13.52%, also the lowest in the recent quarterly data.
These figures suggest a period of subdued profitability, which may have contributed to the stock's downward trajectory. The flat results in the recent quarter contrast with the company's longer-term sales growth, which has been recorded at an annual rate of 31.50%, indicating that while top-line expansion continues, profitability metrics have faced pressure.
Balance Sheet Strength and Efficiency Indicators
Despite the recent price weakness, Indo US Bio-Tech exhibits several positive financial characteristics. The company demonstrates high management efficiency, with a return on capital employed (ROCE) of 27.98%, indicating effective utilisation of capital resources. Additionally, the company maintains a low debt to EBITDA ratio of 0.91 times, reflecting a strong capacity to service its debt obligations.
Valuation metrics also suggest that the stock is trading at a discount relative to its peers' historical averages. The enterprise value to capital employed ratio stands at 2.3, with a ROCE of 16.4%, which points to an attractive valuation framework when viewed in isolation from recent price movements.
Considering Indo US Bio-Tech ? Wait! SwitchER has found potentially better options in Other Agricultural Products and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Other Agricultural Products + beyond scope
- - Top-rated alternatives ready
Shareholding and Market Capitalisation
Indo US Bio-Tech operates within the Other Agricultural Products industry and sector, with promoters holding the majority shareholding stake. The company’s market capitalisation grade is noted as 4, reflecting its size and market presence within its sector.
The stock’s recent day change of -3.43% and its continued trading below all major moving averages highlight the current market sentiment. This is set against a backdrop of a broader market that is trading near its 52-week highs and showing positive momentum, particularly in mid-cap segments.
Summary of Current Concerns and Market Position
Indo US Bio-Tech’s stock has experienced a notable decline to its 52-week low of Rs.112.6, driven by subdued quarterly profitability and a significant underperformance relative to the broader market and its sector. While the company continues to report healthy sales growth and maintains strong financial ratios such as ROCE and debt servicing ability, these factors have not translated into positive price momentum in recent months.
The stock’s position below all key moving averages and its negative returns over the past year contrast with the positive trends in the Sensex and the agricultural sector, indicating company-specific pressures that have weighed on investor confidence.
Conclusion
Indo US Bio-Tech’s fall to a 52-week low underscores the challenges it faces in aligning profitability with its sales growth and market expectations. The stock’s current valuation metrics and financial health provide a nuanced picture, reflecting both strengths and areas of concern. As the company navigates this phase, its market performance remains under close observation amid a generally buoyant market environment.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
